DIPROMON

Multimodular biomarker analysis workflow for Diagnosis, PROgnosis and MONitoring of drug treatment response in bladder cancer

EU FP7-Health project: CORDIS (DIPROMON)

The DIPROMON platform allows design of a novel patient stratification concept, building the tools, technologies and procedures to apply this concept to the bladder cancer patient scenario. The final stage validates the concept in patients with bladder cancer.

Role of Lionex in DIPROMON: To discover, characterise and produce purified biomarkers for test development.

Partners

University of Surrey (UK, coordinator), Emergentec biodevelopment GmbH (Austria), AXO Science SAS (France), Lionex GmbH (Germany), Austrian Institute of Technology (Austria), OnkoTec GmbH (Austria).